PharVision Advisers’s Garrett Motion GTX Stock Holding History

PharVision Advisers’s Portfolio GTX Stock Details GTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,842	Closed	-$216K	–	816
2025 Q3	$216K	Sell	15,842 -17,649	-53%	-$223K	0.12%	451
2025 Q2	$352K	Buy	+33,491	New	+$337K	0.51%	45
2025 Q1	–	Sell	-32,842	Closed	-$297K	–	375
2024 Q4	$297K	Buy	+32,842	New	+$273K	0.25%	160

Other funds holding GTX

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

CCP

Cyrus Capital Partners New York $156M AUM 81.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

GCM

Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PharVision Advisers's GTX Position: Q4 2025 in Review

PharVision Advisers sold out of Garrett Motion (GTX) in Q4 2025, closing a stake of 15,842 shares — an estimated $216K sold.

PharVision Advisers first reported a position in GTX in Q4 2024 and held it in 3 quarters. The position peaked at $352K in Q2 2025. 382 funds tracked by Wall St. Rank hold GTX as of Q4 2025.

PharVision Advisers reported no remaining Garrett Motion position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 15,842 Garrett Motion shares in Q4 2025, an estimated $216K.
PharVision Advisers first reported a position in Garrett Motion in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Garrett Motion position peaked at $352K in Q2 2025.
382 funds tracked by Wall St. Rank held Garrett Motion as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.